TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04385784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise program.
Description: Multimodal exercise program that combines strength, mobility, elasticity and postural control exercises. It develops once a week for a total of 24 weeks. Each session lasts one hour and is carried out in small groups of 8 to 10 people maximum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise program.
Description: Multimodal exercise program that combines strength, mobility, elasticity and postural control exercises. It develops once a week for a total of 24 weeks. Each session lasts one hour and is carried out in small groups of 8 to 10 people maximum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise program.
Description: Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based exercise program.
Description: Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise program.
Description: Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.
Study: NCT01913366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM-PST
Study: NCT03084003

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Graham crackers
Study: NCT03890744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Study: NCT02440685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002 Dose Escalation
Description: Multiple ascending doses of ASN002 assigned by cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002 RD
Description: Recommended dose of ASN002 from Part A
Study: NCT01865643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: The GlideScope is used to assist with difficult tracheal intubation.

Intervention type: DEVICE
Group type: OTHER
Intervention: GlideScope
Description: The GlideScope is used to assist with difficult tracheal intubation.
Study: NCT02750319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Study: NCT01018680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
Study: NCT02750319

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amiodarone
Study: NCT01018680

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken by mouth, once daily for 10 weeks
Study: NCT01749241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate ophthalmic ointment
Description: Thin ribbon ointment to assigned eye twice daily for 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle Ophthalmic Ointment
Description: Thin ribbon ointment to assigned eye twice daily for 14 days
Study: NCT03053531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PockeTalker Hearing Assistive Device (HAD)
Description: Investigators will test impacts of the provision of the HAD on hearing and understanding, and preparation for discharge. Just prior to going home, consented subjects will answer a set of survey questions, using an electronic tablet to support impaired hearing.
Study: NCT02545270

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Level of pneumoperitoneum 12-9-6 mmHg
Description: Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Level of pneumoperitoneum 11-8-5 mmHg
Description: Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Level of pneumoperitoneum 10-7-4 mmHg
Description: Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation.
Study: NCT02852876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral
Study: NCT02750319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01221350

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipoic acid
Description: Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
Study: NCT04791618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health360x plus health coach
Description: Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self management skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health360x only (High tech)
Description: All participants will have access to Helath360x with reminders generated for goal setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health360x only (High tech)
Description: All participants will have access to Helath360x with reminders generated for goal setting.
Study: NCT02156414

Intervention type: PROCEDURE
Intervention: Radical Prostatectomy
Description: Radical Prostatectomy

Intervention type: PROCEDURE
Intervention: Extended Lymphadenectomy
Description: Extended Lymphadenectomy
Study: NCT00904904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin ophthalmic solution
Description: Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
Study: NCT01913366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SG-PST
Study: NCT00904904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Ophthalmic Solution
Description: Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
Study: NCT02411019

Intervention type: BIOLOGICAL
Intervention: GX-188E
Description: In phase II study, 72 patients were assigned to two dose groups (1mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
Study: NCT03117985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no drug
Description: Stopping antiretroviral therapy
Study: NCT01860313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based interactive education
Description: An educational program for training teachers and educators to better recognize mental health problems in adolescents and children

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based interactive education
Description: An educational program for training teachers and educators to better recognize mental health problems in adolescents and children
Study: NCT02852876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2151
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT00968565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium citrate
Description: Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
Study: NCT06097208

Intervention type: BEHAVIORAL
Intervention: community-based health promotion and obesity prevention intervention
Description: The intervention involving measurements of children aged three- to four-years old in kindergartens, parents of the children had the opportunity of individual contact with a community health nurse, and education to kindergartens manager and employees e.g. pedagogues and kitchen staff. as well to parents of children in kindergartens.
Study: NCT01674010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELND005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lamotrigine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valproic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01123044

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Medical Therapy
Description: Under usual care treatment
Study: NCT00268450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Before surgery: given as a 70mg/m2 IV over 60 minutes every 21 days for 4 cycles
Study: NCT04440137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bottle-feeding cessation program
Description: Specific brochure and proper oral hygiene education emphasizing on the benefit of stopping bottle-feeding given to subject
Study: NCT04634617

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT00268450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Before surgery: given as a 1000mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: After surgery: given as a 175 mg/m2 dose ver 3 hours every 21 days for 3 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cysectomy
Study: NCT01373359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 µg sublingual misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 10 IU IM
Study: NCT01293201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAHIST
Description: STAHIST dosed one tablet, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in appearance to IMP, dosed one tablet BID
Study: NCT01062776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dehydration
Description: Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dehydration
Description: Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No dehydration is induced

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No dehydration is induced
Study: NCT05793580

Intervention type: DEVICE
Group type: OTHER
Intervention: Vibrant Soundbridge active middle ear implant
Description: active middle ear implant
Study: NCT01962376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin;Capecitabine
Description: A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin;Capecitabine
Description: A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin;Capecitabine;Bevacizumab
Description: A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin;Capecitabine;Bevacizumab
Description: A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
Study: NCT01860313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text and Video-based education
Description: This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text and Video-based education
Description: This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
Study: NCT00042939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Patients received cetuximab intravenous infusions, via infusion pump or syringe pump, once a week for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Docetaxel was diluted in 100-150 ml of infusion solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Docetaxel was diluted in 100-150 ml of infusion solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest.
Study: NCT02594267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate Injection
Description: Drug: Folotyn (Pralatrexate Injection)~CHOP : Cyclophosphamide, Doxorubicin, Vincristine, \& Prednisone
Study: NCT02082639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: 2 doses intramuscularly in the deltoid muscle of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: 2 doses intramuscularly in the deltoid muscle of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: 2 doses intramuscularly in the deltoid muscle of the dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: 2 doses intramuscularly in the deltoid muscle of the dominant arm
Study: NCT04217798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Subjects will receive niraparib combined with oral etoposide (on day 1-20, every 30 days). After 6-8 cycles, oral etoposide will be terminated. Niraparib will be still given to subjects until disease progression, intolerable toxicity or withdrawal of informed consent.
Study: NCT02699398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Domiciliary VR-based motor rehabilitation
Description: 3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Domiciliary occupational therapy for motor rehabilitation
Description: 3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
Study: NCT02761668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ParS+Ortho 4W
Description: Orthodontics 4 weeks post surgical
Study: NCT01709045

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Multi-sequence MR protocol

Intervention type: RADIATION
Intervention: Dual-Energy Computed Tomography (DECT)
Study: NCT02761668

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ParS+Ortho 6M
Description: Orthodontics 6 months post surgical
Study: NCT00765180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRE vs. NBI
Description: TRE NBI
Study: NCT01709045

Intervention type: OTHER
Intervention: Ultrasound

Intervention type: OTHER
Intervention: Transcranial doppler
Study: NCT04097314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan
Description: 10mg OD Zibotentan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study: NCT00472082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efalizumab
Description: Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
Study: NCT04062279

Intervention type: DIAGNOSTIC_TEST
Intervention: serum alpha synuclein autoantibodies, motor and non motor scales
Description: measuring serum alpha synuclein autoantibodies by ELIZA at baseline assessment
Study: NCT04238117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture treatment
Description: Laser acupuncture therapy (LAT) is a noninvasive technique that involves stimulation of traditional acupoints with low intensity, non thermal laser irradiation.
Study: NCT03010046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX005
Description: Single ascending dose intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX005
Description: Single ascending dose intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIg
Description: IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 0.9% saline intravenous infusion
Study: NCT04131465

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home HIV self-testing
Description: Offer of 3 OraQuick HIV self-test kits
Study: NCT00765180

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRE vs. NBI
Description: TRE NBI
Study: NCT03054649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARMONI® Modular Intraocular Lens System
Description: Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
Study: NCT00865761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 3 mg Extended Release Tablets, single dose
Description: A: Experimental Subjects received Alpharma formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XANAX XR® 3 mg tablets, single dose
Description: B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under fasting conditions
Study: NCT04565574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7090
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7090
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7090
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7090
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Description: Rabeprazole 20 mg (2 tablets, each of 10 mg) oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg
Description: Rifampin 600 mg (4 capsules, each of 150 mg) oral capsule.
Study: NCT03668808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Subjects will use Insulin Degludec (Tresiba) with TRESIBA® FLEXTOUCH® pens as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Subjects will use Insulin Glargine (Lantus) with LANTUS® SOLOSTAR® INSULIN PEN as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRESIBA® FLEXTOUCH®
Description: Subjects will use Tresiba FlexTouch pens when using Tresiba as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LANTUS® SOLOSTAR® INSULIN PEN
Description: Subjects will use Lantus SoloStar insulin pens when using Lantus as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
Study: NCT01808547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-303
Description: 0.075% bromfenac in DuraSite dosed BID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DuraSite Vehicle
Description: DuraSite vehicle dosed BID
Study: NCT02277535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback/Reminder email.
Study: NCT02271932

Intervention type: OTHER
Intervention: Non-operative
Description: Patients will receive only antibiotics and will not undergo appendectomy unless they do not improve or their appendicitis recurs